808 related articles for article (PubMed ID: 16339606)
1. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Glasmacher A; Prentice AG
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
[TBL] [Abstract][Full Text] [Related]
3. Antifungal prophylaxis with itraconazole oral solution in neutropenic patients.
Kibbler CC
Mycoses; 1999; 42 Suppl 2():121-4. PubMed ID: 10865918
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients.
Nucci M; Biasoli I; Akiti T; Silveira F; Solza C; Barreiros G; Spector N; Derossi A; Pulcheri W
Clin Infect Dis; 2000 Feb; 30(2):300-5. PubMed ID: 10671332
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.
Glasmacher A; Prentice A; Gorschlüter M; Engelhart S; Hahn C; Djulbegovic B; Schmidt-Wolf IG
J Clin Oncol; 2003 Dec; 21(24):4615-26. PubMed ID: 14673051
[TBL] [Abstract][Full Text] [Related]
6. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
Vardakas KZ; Michalopoulos A; Falagas ME
Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
[TBL] [Abstract][Full Text] [Related]
7. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto.
Menichetti F; Del Favero A; Martino P; Bucaneve G; Micozzi A; Girmenia C; Barbabietola G; Pagańo L; Leoni P; Specchia G; Caiozzo A; Raimondi R; Mandelli F
Clin Infect Dis; 1999 Feb; 28(2):250-5. PubMed ID: 10064240
[TBL] [Abstract][Full Text] [Related]
8. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
12. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis.
Arca E; Taştan HB; Akar A; Kurumlu Z; Gür AR
J Dermatolog Treat; 2002 Mar; 13(1):3-9. PubMed ID: 12006131
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.
Morgenstern GR; Prentice AG; Prentice HG; Ropner JE; Schey SA; Warnock DW
Br J Haematol; 1999 Jun; 105(4):901-11. PubMed ID: 10554799
[TBL] [Abstract][Full Text] [Related]
14. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial.
Timmers GJ; Zweegman S; Simoons-Smit AM; van Loenen AC; Touw D; Huijgens PC
Bone Marrow Transplant; 2000 Apr; 25(8):879-84. PubMed ID: 10808210
[TBL] [Abstract][Full Text] [Related]
15. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.
Harousseau JL; Dekker AW; Stamatoullas-Bastard A; Fassas A; Linkesch W; Gouveia J; De Bock R; Rovira M; Seifert WF; Joosen H; Peeters M; De Beule K
Antimicrob Agents Chemother; 2000 Jul; 44(7):1887-93. PubMed ID: 10858349
[TBL] [Abstract][Full Text] [Related]
16. Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia.
Myoken Y; Sugata T; Kyo T; Fujihara M; Mikami Y
J Periodontol; 2002 Jan; 73(1):33-8. PubMed ID: 11846198
[TBL] [Abstract][Full Text] [Related]
17. [Prevention of fungal infections in children and adolescents with cancer].
Groll AH; Ritter J; Müller FM
Klin Padiatr; 2001 Sep; 213 Suppl 1():A50-68. PubMed ID: 11577364
[TBL] [Abstract][Full Text] [Related]
18. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
[TBL] [Abstract][Full Text] [Related]
19. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
[TBL] [Abstract][Full Text] [Related]
20. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
Huijgens PC; Simoons-Smit AM; van Loenen AC; Prooy E; van Tinteren H; Ossenkoppele GJ; Jonkhoff AR
J Clin Pathol; 1999 May; 52(5):376-80. PubMed ID: 10560360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
